Latest Articles

Publication Date
All News Scientific
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire

Published: Dec. 3, 2024, 10:01 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance UK

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance UK

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
Study identifies key risk factors for recurrence in early endometrial cancer after hormonal therapy - KBR

Study identifies key risk factors for recurrence in early endometrial cancer after hormonal therapy KBR

Published: Dec. 3, 2024, 6:49 a.m.
Read Full Article
The prognostic value of tumor microenvironment in endometrioid type endometrial cancer: Effect of CD44 on oncologic outcome - ResearchGate

The prognostic value of tumor microenvironment in endometrioid type endometrial cancer: Effect of CD44 on oncologic outcome ResearchGate

Published: Dec. 3, 2024, 6:33 a.m.
Read Full Article
Biotechnological progresses in modelling the human endometrium: the evolution of current in vitro techniques and emerging trends.

The endometrium plays a fundamental role in the reproductive system yet many etiologies of infertility-related endometrial diseases such as endometriosis, adenomyosis, Asherman's syndrome or endometrial cancer remain unknown. There are …

Published: Dec. 3, 2024, midnight
Read Full Article
cell culture endometrial diseases endometrial modelling female reproduction in vitro techniques tissue engineering
Exploring Treatment Options Through Genomic Sequencing in Endometrial Cancer - Cancer Network

Exploring Treatment Options Through Genomic Sequencing in Endometrial Cancer Cancer Network

Published: Dec. 2, 2024, 7:02 p.m.
Read Full Article
HALP Score Predicts Prognosis in Intermediate-Risk Endometrial Cancer - Physician's Weekly

HALP Score Predicts Prognosis in Intermediate-Risk Endometrial Cancer Physician's Weekly

Published: Nov. 29, 2024, 11:49 a.m.
Read Full Article
Meta-analysis of clinicopathologic features of endometrial cancer molecular staging - Frontiers

Meta-analysis of clinicopathologic features of endometrial cancer molecular staging Frontiers

Published: Nov. 28, 2024, 5 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!